Evidence map›Paper›PMID 34366633›Full record

ArticleWorld journal of gastroenterology2021

HER2-positive adenocarcinoma arising from heterotopic pancreas tissue in the duodenum: A case report.

Yoshifumi S Hirokawa, Takashi Iwata, Yoshinaga Okugawa, Koji Tanaka, Hiroyuki Sakurai, Masatoshi Watanabe

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Primary adenocarcinoma from a gastric heterotopic pancreas: A case report.World journal of gastrointestinal endoscopy · 2025
    Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. OncoPanBiomedicines · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Yoshifumi S HirokawaDepartment of Oncologic Pathology, Mie University Graduate School of Medicine, Mie 5148507, Japan. ultray2k@med.mie-u.ac.jp.
Takashi IwataCancer Center, Aichi Medical University, Aichi 4801195, Japan.
Yoshinaga OkugawaDepartment of Genomic Medicine, Mie University Hospital, Mie 5148507, Japan.
Koji TanakaDepartment of Surgery, IGA City General Hospital, Mie 5180823, Japan.
Hiroyuki SakuraiHepato-biliary-pancreatic and Transplant Surgery, Mie University Hospital, Mie 5148507, Japan.
Masatoshi WatanabeDepartment of Oncologic Pathology, Mie University Graduate School of Medicine, Mie 5148507, Japan.
Mie University · JPMie University Hospital · JPAichi Medical University · JPMisawa City Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdenocarcinoma originating from heterotopic pancreas tissue is a rare disease. Furthermore, to our knowledge, no HER2-positive cases in the duodenum have been reported in the scientific literature nor has the efficacy of trastuzumab treatment for the disease been reported. CASE SUMMARY: A 65-year-old woman whose clinical diagnosis was unresectable advanced duodenal cancer with HER2 overexpression responded well to trastuzumab chemotherapy. The main tumor in the duodenum reduced drastically. The patient underwent pancreaticoduodenectomy and lymph node dissection. A small number of cancer cells remained in the submucosal layer of the duodenum and pancreas head. After histological and immunohistochemical examination, the patient was diagnosed with duodenal adenocarcinoma originating from heterotopic pancreas tissue.

conclusionTrastuzumab treatment is effective in HER2-positive adenocarcinoma originating from heterotopic pancreas tissue in the duodenum.

Indexed as

AdenocarcinomaChoristomaAgedDuodenumFemaleHumansPancreasPancreaticoduodenectomyCase reportConversion surgeryDuodenal cancerHeterotopic pancreas tissueHuman epidermal growth factor receptor 2Trastuzumab

Identifiers

PMID34366633
PMCPMC8326258
OpenAlexW3186080095

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.